Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The closing price of Regenxbio Inc (NASDAQ: RGNX) was $7.95 for the day, up 1.27% from the previous closing price of $7.85. In other words, the price has increased by $1.27 from its previous closing price. On the day, 0.66 million shares were traded. RGNX stock price reached its highest trading level at $8.04 during the session, while it also had its lowest trading level at $7.4.
Ratios:
Our analysis of RGNX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.05 and its Current Ratio is at 3.05. In the meantime, Its Debt-to-Equity ratio is 0.48 whereas as Long-Term Debt/Eq ratio is at 0.37.
On June 07, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $38.Goldman initiated its Buy rating on June 07, 2024, with a $38 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 30 ’24 when VITTAL VASISTA bought 20,041 shares for $7.41 per share.
KARABELAS ARGERIS N sold 10,000 shares of RGNX for $101,052 on Oct 01 ’24. The Director now owns 11,286 shares after completing the transaction at $10.11 per share. On Sep 03 ’24, another insider, KARABELAS ARGERIS N, who serves as the Director of the company, sold 10,000 shares for $11.56 each. As a result, the insider received 115,588 and left with 11,286 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RGNX now has a Market Capitalization of 393883520 and an Enterprise Value of 284234304. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.67 while its Price-to-Book (P/B) ratio in mrq is 1.31. Its current Enterprise Value per Revenue stands at 3.371 whereas that against EBITDA is -1.271.
Stock Price History:
The Beta on a monthly basis for RGNX is 1.29, which has changed by -0.3828616 over the last 52 weeks, in comparison to a change of 0.24440956 over the same period for the S&P500. Over the past 52 weeks, RGNX has reached a high of $28.80, while it has fallen to a 52-week low of $6.56. The 50-Day Moving Average of the stock is -9.03%, while the 200-Day Moving Average is calculated to be -32.87%.
Shares Statistics:
RGNX traded an average of 1.28M shares per day over the past three months and 1394140 shares per day over the past ten days. A total of 49.53M shares are outstanding, with a floating share count of 44.68M. Insiders hold about 9.82% of the company’s shares, while institutions hold 90.84% stake in the company. Shares short for RGNX as of 1735603200 were 6042356 with a Short Ratio of 4.73, compared to 1732838400 on 5259878. Therefore, it implies a Short% of Shares Outstanding of 6042356 and a Short% of Float of 15.950000000000001.
Earnings Estimates
The dynamic stock of Regenxbio Inc (RGNX) is currently attracting attention from 8.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$1.17, with high estimates of -$1.04 and low estimates of -$1.35.
Analysts are recommending an EPS of between -$4.03 and -$5.47 for the fiscal current year, implying an average EPS of -$4.78. EPS for the following year is -$0.59, with 8.0 analysts recommending between $2.63 and -$2.91.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 8 analysts. It ranges from a high estimate of $31M to a low estimate of $15M. As of the current estimate, Regenxbio Inc’s year-ago sales were $22.21MFor the next quarter, 8 analysts are estimating revenue of $19.85M. There is a high estimate of $22.4M for the next quarter, whereas the lowest estimate is $15M.
A total of 10 analysts have provided revenue estimates for RGNX’s current fiscal year. The highest revenue estimate was $94.51M, while the lowest revenue estimate was $77.11M, resulting in an average revenue estimate of $87.11M. In the same quarter a year ago, actual revenue was $90.24MBased on 10 analysts’ estimates, the company’s revenue will be $321.24M in the next fiscal year. The high estimate is $495.52M and the low estimate is $246.6M.
